Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL)

CUSIP: 55083R104

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock par value $0.0001 per share
Total 13F shares
2,440,673
Total 13F value
$21,579,143
Holder snapshot 6 signals
Share change
-149,734,707
SEC-reported price per share
$8.84
Number of holders
6
Value change
-$465,374,774
Number of buys
1
Number of sells
109
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
23,360,878

Security key

55083R104

Report period

Q2 2025

Institutions

6

Top holders

6

LYEL full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 Lyell Immunopharma, Inc. SEC filings Lyell Immunopharma, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of LYEL - Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Foresite Capital Fund IV,...
Disclosed value leader
Foresite Capital Fund IV,...
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G 13F Lead comparable stake: 9.2% 13D/G row: Foresite Capital Fund IV, L.P. Showing 1-6 of 15 holder rows.

Quick read

Foresite Capital Fund IV, L.P. leads the comparable SEC ownership view at 9.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Foresite Capital Fund IV, L.P.'s linked filing trail.
Comparable ownership Top 5
Foresite Capital Fund IV, L.P. 9.2%
BlackRock, Inc. 4.5%
MWG Management Ltd. 86%
Foresite Capital Management IV, LLC 69%
Orland Properties Ltd 65%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Foresite Capital Fund IV, L.P.
13D/G
James B. Tananbaum
13D/G
9.2%
$12,766,089
27,161,892 shares
 +$3,611,010 31 Mar 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
4.5%
from 13D/G
$6,844,206
12,721,571 shares
 — 31 Mar 2025
MWG Management Ltd.
13F
Company
13F
86%
$10,847,335
20,162,332 shares
 — 31 Mar 2025
Foresite Capital Management IV, LLC
13F
Company
13F
69%
$8,612,303
16,007,999 shares
 — 31 Mar 2025
Orland Properties Ltd
13F
Company
13F
65%
$8,150,743
15,093,969 shares
 — 31 Mar 2025
Decheng Capital LLC
13F
Company
13F
51%
$6,407,225
11,909,341 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
6
Shares
2,440,673
Rows available
6
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
111
Q2 2025 holders
6
Holder diff
-105
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .